139 related articles for article (PubMed ID: 18684245)
1. Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase.
Mullin JM; Valenzano MC; Whitby M; Lurie D; Schmidt JD; Jain V; Tully O; Kearney K; Lazowick D; Mercogliano G; Thornton JJ
Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1317-25. PubMed ID: 18684245
[TBL] [Abstract][Full Text] [Related]
2. The use of acid-decreasing medication in veteran patients with gastro-oesophageal reflux disorder with and without Barrett's oesophagus.
El-Serag HB; Wieman M; Richardson P
Aliment Pharmacol Ther; 2008 Jun; 27(12):1293-9. PubMed ID: 18363892
[TBL] [Abstract][Full Text] [Related]
3. Esomeprazole reduces gastroesophageal reflux after beer consumption in healthy volunteers.
Franke A; Hepp C; Harder H; Beglinger C; Singer MV
Scand J Gastroenterol; 2008; 43(12):1425-31. PubMed ID: 18924018
[TBL] [Abstract][Full Text] [Related]
4. Esomeprazole: a proton pump inhibitor.
Vachhani R; Olds G; Velanovich V
Expert Rev Gastroenterol Hepatol; 2009 Feb; 3(1):15-27. PubMed ID: 19210109
[TBL] [Abstract][Full Text] [Related]
5. The effects of high-dose esomeprazole on gastric and oesophageal acid exposure and molecular markers in Barrett's oesophagus.
Abu-Sneineh A; Tam W; Schoeman M; Fraser R; Ruszkiewicz AR; Smith E; Drew PA; Dent J; Holloway RH
Aliment Pharmacol Ther; 2010 Oct; 32(8):1023-30. PubMed ID: 20937048
[TBL] [Abstract][Full Text] [Related]
6. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
[TBL] [Abstract][Full Text] [Related]
7. Effects of long-term PPI treatment on producing bowel symptoms and SIBO.
Compare D; Pica L; Rocco A; De Giorgi F; Cuomo R; Sarnelli G; Romano M; Nardone G
Eur J Clin Invest; 2011 Apr; 41(4):380-6. PubMed ID: 21128930
[TBL] [Abstract][Full Text] [Related]
8. Changes in gene expression of gastric mucosa during therapeutic acid inhibition.
Nørsett KG; Laegreid A; Kusnierczyk W; Langaas M; Ylving S; Fossmark R; Myhre S; Falkmer S; Waldum HL; Sandvik AK
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):613-23. PubMed ID: 18679062
[TBL] [Abstract][Full Text] [Related]
9. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease.
Wu JC; Lai LH; Chow DK; Wong GL; Sung JJ; Chan FK
Neurogastroenterol Motil; 2011 Feb; 23(2):155-60, e31. PubMed ID: 21087355
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system.
Vasiliadis KV; Viazis N; Vlachogiannakos J; Sgouros SN; Stefanidis G; Archimandritis A; Karamanolis DG
Am J Gastroenterol; 2010 Feb; 105(2):308-13. PubMed ID: 19809412
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitor influence on reflux in Barrett's oesophagus.
Smythe A; Troy GP; Ackroyd R; Bird NC
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):881-7. PubMed ID: 18794602
[TBL] [Abstract][Full Text] [Related]
12. Impact of compliance with proton pump inhibitors on NSAID treatment.
Duh MS; Gosselin A; Luo R; Lohoues H; Lewis BE; Crawley JA
Am J Manag Care; 2009 Oct; 15(10):681-8. PubMed ID: 19845420
[TBL] [Abstract][Full Text] [Related]
13. Esomeprazole for the treatment of GERD in infants ages 1-11 months.
Winter H; Gunasekaran T; Tolia V; Gottrand F; Barker PN; Illueca M
J Pediatr Gastroenterol Nutr; 2012 Jul; 55(1):14-20. PubMed ID: 22241513
[TBL] [Abstract][Full Text] [Related]
14. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age.
Sandström M; Davidson G; Tolia V; Sullivan JE; Långström G; Lundborg P; Brown K
Clin Ther; 2012 Aug; 34(8):1828-38. PubMed ID: 22832034
[TBL] [Abstract][Full Text] [Related]
15. Randomised clinical trial: identification of responders to short-term treatment with esomeprazole for dyspepsia in primary care - a randomised, placebo-controlled study.
Meineche-Schmidt V; Christensen E; Bytzer P
Aliment Pharmacol Ther; 2011 Jan; 33(1):41-9. PubMed ID: 21083590
[TBL] [Abstract][Full Text] [Related]
16. Esomeprazole for asthma.
Wise MP; Saayman AG; Frost PJ
N Engl J Med; 2009 Jul; 361(2):207; author reply 207-8. PubMed ID: 19593856
[No Abstract] [Full Text] [Related]
17. Relationship between symptom response and esophageal pH level on standard dose of esomeprazole treatment for gastroesophageal reflux disease.
Peng S; Xiong LS; Xiao YL; Wang AJ; Lin JK; Hu PJ; Chen MH
Chin Med J (Engl); 2010 Aug; 123(15):2012-7. PubMed ID: 20819534
[TBL] [Abstract][Full Text] [Related]
18. Transepithelial leak in Barrett's esophagus patients: the role of proton pump inhibitors.
Farrell C; Morgan M; Tully O; Wolov K; Kearney K; Ngo B; Mercogliano G; Thornton JJ; Valenzano MC; Mullin JM
World J Gastroenterol; 2012 Jun; 18(22):2793-7. PubMed ID: 22719187
[TBL] [Abstract][Full Text] [Related]
19. Correlation between oesophageal acid exposure and dyspeptic symptoms in patients with nonerosive reflux disease.
Sarnelli G; De Giorgi F; Efficie E; Aprea G; Masone S; Savarese MF; Esposito I; Russo L; Cuomo R
Eur J Gastroenterol Hepatol; 2008 Apr; 20(4):264-8. PubMed ID: 18334868
[TBL] [Abstract][Full Text] [Related]
20. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors.
Hawkey C; Talley NJ; Yeomans ND; Jones R; Sung JJ; Långström G; Naesdal J; Scheiman JM;
Am J Gastroenterol; 2005 May; 100(5):1028-36. PubMed ID: 15842575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
